Blue Star revenue outpaced profit as margins contracted

Blue Star reported Q2FY27 revenue growth of 21.0% to Rs 2,930.95 crore, while profit before tax before exceptional items rose only 1.6% to Rs 134.28 crore. Higher material costs that were not fully passed on and project execution delays reduced margins in its two largest segments, while a Rs 23.02 crore exceptional gain supported reported net profit.

Why did Blue Star’s revenue grow faster than profit in Q2FY27?

Blue Star’s revenue grew faster than operating profit because sales increased 21.0% while earnings before interest, tax, depreciation and amortisation, excluding other income, increased 10.5%. Revenue from operations rose from Rs 2,422.37 crore in Q2FY26 to Rs 2,930.95 crore in Q2FY27, whereas EBITDA increased from Rs 183.41 crore to Rs 202.58 crore.

The gap widened below EBITDA. Profit before tax before exceptional items increased by Rs 2.12 crore to Rs 134.28 crore from Rs 132.16 crore, while reported net profit rose 25.4% to Rs 123.91 crore from Rs 98.78 crore. The reported profit included a Rs 23.02 crore exceptional gain on the sale of the MedTech business, and earnings per share, not annualised, rose to Rs 6.03 from Rs 4.80.

The Q2FY27 comparison shows that reported net-profit growth did not match the change in pre-exceptional profit before tax. Blue Star disclosed that the Rs 23.02 crore gain from the MedTech sale was an exceptional item, while the underlying operating segments encountered material-cost escalation and project execution delays.

Which Blue Star segments had margin pressure?

Blue Star’s Unitary Products segment recorded the largest margin decline, despite 29.4% revenue growth to Rs 897.66 crore in Q2FY27 from Rs 693.81 crore. An extended summer supported demand for room air-conditioners, but the segment result fell 51.4% to Rs 20.74 crore from Rs 42.72 crore.

Unitary Products’ earnings before interest and tax, or EBIT, margin declined by 390 basis points to 2.3% from 6.2%; a basis point is one-hundredth of a percentage point. Blue Star said periodic price increases passed on only part of material-cost escalation. The Commercial Refrigeration business began seeing demand revive in Deep Freezers, Bottled Water Dispensers and Storage Water Coolers.

Electro-Mechanical Projects and Commercial Air Conditioning Systems remained the larger segment, with revenue rising 16.3% to Rs 1,935.99 crore from Rs 1,664.21 crore. Its segment result nevertheless declined 9.5% to Rs 133.15 crore from Rs 147.14 crore, and its EBIT margin decreased by 190 basis points to 6.9% from 8.8%.

Blue Star attributed that segment’s result to robust product-business revenue, subdued project-business activity caused by execution delays, and material costs that could not be fully passed on. The segment continued US heat-pump supplies despite supply-chain and logistics challenges, and management said strong order enquiries supported its expectation of significant growth in order inflows.

What lifted Blue Star’s reported Q2FY27 net profit?

Blue Star’s reported Q2FY27 net profit was lifted by a Rs 23.02 crore exceptional gain on the MedTech business sale completed on August 31, 2026. Net profit increased by Rs 25.13 crore year on year to Rs 123.91 crore, compared with a Rs 2.12 crore increase in profit before tax before exceptional items.

Professional Equipment and Industrial Solutions also improved materially in Q2FY27. Its revenue increased 51.2% to Rs 97.30 crore from Rs 64.35 crore, while segment result increased 274.4% to Rs 23.10 crore from Rs 6.17 crore. EBIT margin rose by 1,410 basis points to 23.7% from 9.6%.

Blue Star said the improved margin reflected a write-back of warranty provisions after MedTech product-related obligations ceased. It also said Industrial Solutions continued to grow with demand from manufacturing and testing sectors, a mechanism distinct from the cost and execution pressures reported in the two larger segments.

Did Blue Star’s first-half results show the same gap?

Blue Star’s H1FY27 results also showed revenue growth without corresponding growth in underlying profit. Revenue from operations increased 16.7% to Rs 6,308.87 crore from Rs 5,404.62 crore in H1FY26, while EBITDA excluding other income declined 1.5% to Rs 377.53 crore from Rs 383.41 crore.

Profit before tax before exceptional items fell 12.1% to Rs 259.70 crore from Rs 295.40 crore in H1FY26. Reported H1FY27 net profit still increased 25.4% to Rs 226.42 crore from Rs 219.60 crore, while earnings per share, not annualised, rose 3.1% to Rs 11.01 from Rs 10.68.

Blue Star reported Rs 32.19 crore of exceptional gains in H1FY27, comprising the Rs 23.02 crore MedTech-sale gain and Rs 9.17 crore profit on the sale of property. The first-half EBITDA decline of Rs 5.88 crore contrasts with the Rs 19.17 crore Q2FY27 increase, showing that the six-month outcome included weaker profitability before exceptional items.

What should readers track in Blue Star’s next results?

Blue Star reported a carried-forward order book of Rs 7,229.22 crore, 1.5% above the cited Rs 7,120.44 crore figure as of September 30, 2026. The order book is relevant because project-business revenue was subdued by execution delays, and management has said it expects significant growth in order inflows from strong enquiries.

The H1FY27 balance-sheet presentation reported net cash of Rs 289.43 crore, compared with net borrowings of Rs 417.06 crore in H1FY26. Net debt to equity moved to negative 0.08 times from 0.13 times, net worth increased to Rs 3,486.70 crore from Rs 3,110.96 crore, and capital turns remained at 4.0 times.

The disclosed operating variables remain material-cost recovery, project execution timing and US heat-pump supply-chain and logistics conditions. Demand trends in room air-conditioners, commercial refrigeration, Industrial Solutions and testing markets will also affect whether revenue growth converts into segment profit.

Conclusion

Blue Star’s Q2FY27 and H1FY27 results show that revenue expansion did not translate proportionately into operating profit. Q2FY27 revenue increased 21.0%, but incomplete material-cost recovery reduced margins in Unitary Products and Electro-Mechanical Projects and Commercial Air Conditioning Systems, while the Rs 23.02 crore MedTech-sale gain supported reported profit.

The next results should show whether Blue Star’s stated expectation of significant order-inflow growth develops alongside execution of its Rs 7,229.22 crore carried-forward order book. Readers should also watch whether pricing recovers more material costs, whether project delays ease, and whether the commercial refrigeration demand revival continues after the August 31, 2026 MedTech sale.